GemPharmatech branches out with preclinical research sites in U.S.

By The Science Advisory Board staff writers

February 22, 2021 -- China's GemPharmatech, a provider of laboratory animals, has launched new research sites in the U.S. that will house 6,000 research models.

The Nanjing, China-based company said that it has a large collection of about 15,000 models, including conditional knockout, knockout mice, and immune-deficient mice, generated using gene editing technologies. The new facilities are based in Massachusetts and California.

The company hopes to provide tools and services faster and closer to its research and development customers, including large pharmaceutical and biotechnology companies, contract research organizations (CROs), universities, and research institutions in the U.S.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.